Gout is the most common inflammatory arthritis, affecting about 9.2 million US adults (3.9%) in 2007 to 2016 data cited by the American College of Rheumatology (ACR). Urate crystals cause joint flares lasting one to two weeks. The 2012 ACR guideline preferred treating flares within 24 hours, yet AMN Healthcare's 2025 survey found an average 23.5-day family medicine wait across 15 metro areas (31 days overall).

People often search for gout treatment online to get convenient care without recurring subscriptions. Ask yourself: do you want another service with all its requirements, or do you want your own expert doctor? If you want what another company bundles beyond the doctor, it is a strong option. If you wanted a doctor directly, FutureClinic gives you that with nothing attached.

On FutureClinic, no form is approved in bulk. A specific doctor reads your whole case and answers by message, recording a Human Signature (a short live video or voice note) with your plan. Every doctor is a licensed physician with an MD, DO or MBBS degree, never a nurse practitioner or physician assistant. Real care takes hours, not seconds, so replies typically come within a few hours, almost always the same day or the next.

What does having the same doctor over months do for gout?

NIAMS notes primary care providers manage most gout, one of the most controllable arthritides. Yet per the 2020 ACR guideline, urate-lowering therapy (ULT) use has stalled for two decades, with the lowest adherence among seven chronic conditions. Care has two jobs: calming flares and lowering urate long term to prevent flares and shrink tophi. Messaging the same doctor in the same chat over months builds trust to try treatments and track progress: keeping a home flare plan, swapping a pill that causes side effects, and adjusting doses by lab results.

Per NIAMS, gout often coexists with high blood pressure, kidney disease, obesity, diabetes, kidney stones, or heart disease, and diuretics or low-dose aspirin can raise the risk of gout. Your doctor can help with other problems in their specialty, like switching hydrochlorothiazide to losartan when feasible. Every FutureClinic doctor you see works from one medical record.

We believe AI is a tool for doctors, and the doctor is in charge of every case. Nuanced health problems need one-to-one attention, and only an expert knows when AI errs. FutureClinic's AI works behind the scenes like a chief resident, gathering history, medicines, labs, and photos, and never gives medical advice by itself. After you confirm the summary, one of over 300 doctors writes back. Our physicians span more than 60 specialties, generalists and specialists alike.

AI gout treatment: how doctors treat a flare by message

The 2020 ACR guideline and 2017 ACP guideline (now inactive) strongly recommend colchicine, NSAIDs, or glucocorticoids first line. None is a controlled substance. If your doctor decides it's right for you, oral options include:

• Colchicine tablets: The colchicine label and ACR 2020 recommend low-dose colchicine: 1.2 mg at onset, then 0.6 mg an hour later. In the label trial, 38% on low-dose had at least 50% pain relief at 24 hours vs 33% on high-dose (4.8 mg) and 16% on placebo, with fewer digestive side effects (26% vs 77%). (Capsules, generic Mitigare, are for prevention only.)
• Oral NSAIDs: Naproxen or indomethacin (boxed warning for cardiovascular and gastrointestinal risks).
• Oral glucocorticoids: A 2021 Cochrane review found systemic steroids and NSAIDs probably relieve pain equally, and NSAIDs probably cause more side effects (moderate-certainty evidence). ACR 2012 suggested prednisone (5 to 10 days or tapered) or methylprednisolone; ACR 2020 adds ice and a home "medication-in-pocket" plan.

Preventing flares: urate-lowering therapy and the labs that guide it

ACR 2020 strongly recommends ULT for tophi, gout joint damage, or frequent flares (two or more yearly), and conditionally after multiple flares or a first flare with stage 3 or worse kidney disease, urate above 9 mg/dL, or kidney stones. Because high uric acid levels "don't always mean you have gout", ACR 2020 conditionally recommends against ULT without gout. Established ULT continues during flares. If your doctor decides it's right for you:

• Allopurinol: ACR 2020's preferred first-line ULT, including in stage 3 or worse kidney disease. Doctors start allopurinol at 100 mg daily or less (50 mg for eGFR above 30 to 60) and raise it every 2 to 5 weeks until urate is below 6 mg/dL, up to 800 mg daily (ACR 2012 noted 300 mg or less misses target in over half of patients).
• Febuxostat and probenecid: Febuxostat (40 to 80 mg daily) is second line; its boxed warning reflects higher cardiovascular death than allopurinol in the CARES trial (1.5 vs 1.1 per 100 patient-years). Probenecid may not work at GFR 30 mL/min or less, is not advised with uric acid stones, and cannot be taken with aspirin; ACR 2020 strongly prefers allopurinol or febuxostat at kidney disease stage 3 or worse.
• Prophylaxis: ACR 2020 strongly recommends 3 to 6 months of colchicine, an NSAID, or prednisone when starting ULT, and the 2017 ACP review found daily colchicine or NSAID prevention cuts flare risk by at least half.

Where a 2017 commentary contrasted "treat to avoiding symptoms versus treat to target," ACR 2020 strongly recommends adjusting ULT until urate is below 6 mg/dL, and conditionally recommends continuing ULT indefinitely. Nurse-led treat-to-target care in a 2018 Lancet trial (517 UK patients) reached target in 95% at two years vs 30% with usual care, and remote pharmacist trials doubled target rates (35% vs 13%; 30% vs 15%). Your doctor can order discounted local labs: baseline uric acid, blood counts, liver and kidney panels, and urate checks every 2 to 5 weeks. Your doctor can also order HLA-B*58:01 testing before allopurinol for people of Southeast Asian descent and African American patients, where a lab offers it.